Recombinant Human Coagulation factor VII(F7),partial

Code CSB-YP007930HU
Size US$1916
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity Greater than 85% as determined by SDS-PAGE.
Target Names F7
Uniprot No. P08709
Research Area Cardiovascular
Alternative Names coagulation factor VII (serum prothrombin conversion accelerator); Coagulation factor VII; Eptacog alfa ; F7; FA7_HUMAN; Factor VII ; Factor VII heavy chain; Factor VII light chain; FVII coagulation protein ; OTTHUMP00000018733; OTTHUMP00000018734; Proconvertin; Serum prothrombin conversion accelerator; SPCA
Species Homo sapiens (Human)
Source Yeast
Expression Region 61-212aa
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight 19.0 kDa
Protein Length Partial
Tag Info N-terminal 6xHis-tagged
Form Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Target Data

Function Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium.
Gene References into Functions
  1. TF-FVIIa/trypsin-mediated PAR2 activation leads to enhanced MMP-2 expression in human breast cancer cells contributing to tumor progression. PMID: 29870887
  2. The current meta-analysis suggested that polymorphism of R353Q in factor VII was not associated with the MI risk. PMID: 30278561
  3. The obtained results suggest a possible protective role of Gln353 and -122C alleles in Recurrent Miscarriage. PMID: 27504943
  4. FVIIa-antithrombin levels in early and late preeclampsia PMID: 28887028
  5. model predicts that small vesicles promote activation of FX by the extrinsic tenase (VIIa/TF) significantly better than large vesicles PMID: 28935233
  6. Low levels of FVII:C and FVIIa reflected the degree of consumption of the coagulation factor among paediatric sepsis patients with disseminated intravascular coagulation. PMID: 28492702
  7. Report a good correlation between the type of F7 mutation and/or polymorphisms and FVII:C levels, without a direct link between FVII:C and bleeding tendency in factor VII deficiencies. PMID: 28447100
  8. Polymorphism rs6046 of the FVII gene is associated with the development of fetal growth retardation in Central Russia. PMID: 28544373
  9. A common pathogenic mechanism, possibly a defective folding of the mutant proteins, was triggered by the FVII mutations. The misfolded state led to impaired trafficking of these proteins causing Endoplasmic reticulum retention, which would explain the low to very low FVII plasma levels observed in patients carrying these mutations. PMID: 29246447
  10. FVIIa-antithrombin but not FVIIa is a ligand for LRP1, and LRP1 contributes to the clearance of FVIIa-antithrombin in vivo PMID: 27614059
  11. heterozygotes for FVII deficiency show rare bleeding manifestations which are also present in the unaffected family members with normal FVII levels. This indicates that Factor VII activity levels played no role in the occurrence of the bleeding symptoms. Furthermore, FVII levels of around 0.40 IU/dl are capable of assuring a normal hemostasis. PMID: 28176610
  12. plasma FVIIa-AT has a thrombophilic role in total and cardiovascular mortality risk in patients with clinically stable stable coronary artery PMID: 27061056
  13. Family-based association study revealed that the G allele of Protein Z rs2273971, and haplotypes GA, CG, and CGA of Protein Z and factor VII had a significant effect on cerebral hemorrhage susceptibility. PMID: 27350683
  14. Our study findings suggest a link between FVII and AR in prostate cancer pathogenesis. PMID: 27434295
  15. Suggest that the hemostatic effect of pharmacological doses of rFVIIa in antibody-induced hemophilia mice stems from a TF-independent mechanism PMID: 26727350
  16. Large deletions play a minor but essential role in the mutational spectrum of the F7 and F10 genes. Copy number analyses (e. g. MLPA) should be considered if sequencing cannot clarify the underlying reason of an observed coagulopathy. Of note, in cases of combined FVII/FX deficiency, a deletion of the two contiguous genes might be part of a larger chromosomal rearrangement. PMID: 26540129
  17. Holders of the R allele had significantly higher activity of coagulation factor F7 (97.66 +/- 15.48 against 83.37 +/- 15.16, p = 0.002) and factor F2 (107.45 +/- 6.03 against 103.75 +/- 6.81, p = 0.023) than holders of the Q allele PMID: 27215039
  18. The aim of the study was to evaluate the molecular basis behind low levels of FVII activity (FVII:C) levels in a cohort of Brazilian patients. PMID: 25828579
  19. Decreased plasma levels of FVIIa in patients with deep vein thrombosis may indicate ongoing consumption of FVIIa and suggest a contributory role for TF in venous thrombus formation. PMID: 25891834
  20. The story of FVII well summarizes the efforts of both theoretical and clinical approaches in the characterization of a coagulation disorder, that is, among the rare bleeding conditions, most frequently encountered in clinical practice. PMID: 25973586
  21. Identified are the FVII gene mutations in the Chinese Han population of four unrelated FVII-deficient patients, and the effect of these mutations on the function of FVII molecule level has also been elucidated. PMID: 25767893
  22. Letter: large volume of distribution of rFVIIa explains the persistence of some clotting potential when FVII:C is no longer detectable in plasma of patients with inherited FVII deficiency. PMID: 24763923
  23. Structural differences in the carboxyl-terminus between the inherited FVII and the therapeutic molecules contributed to the immune response. A naturally-occurring, poorly secreted and 5-residue truncated FVII (FVII-462X) escaped inhibition. PMID: 25104096
  24. Polymorphism R353Q (coagulation factor VII) does not represent a protective or risk factor for acute myocardial infarction in young Mexican individuals PMID: 25393858
  25. Two heterozygous mutations of F7, g.11349G>A and g.11482T>G, is associated with hereditary coagulation factor deficiency. PMID: 25863091
  26. factor VIIa improved heat intolerance by attenuating hypothalamic neuronal apoptosis and damage. PMID: 25033928
  27. Results show that the conformational allosteric activation signal extends to the EGF1 domain in the light chain of factor VIIa (FVIIa). PMID: 25344622
  28. F7-323Ins10 was associated with lower factor VII levels, but not with individual intraventricular hemorrhage risk in preterm infants. PMID: 25179312
  29. Decanucleotide insertion polymorphism of factor VII significantly influences the risk of thrombosis in patients with essential thrombocythemia. PMID: 24617727
  30. High Coagulation factor VII expression is associated with breast cancer. PMID: 25447311
  31. Persistently high levels of factor VII is associated with insulin resisitance. PMID: 24344794
  32. The variability in Factor VII throughout the menstrual cycle in premenopausal women is no greater than for postmenopausal women or men. PMID: 24382103
  33. The obtained results suggest a probable protective role of -323P10 allele against the risk of miscarriage in women with > or = 3 recurrent pregnancy losses. PMID: 25219139
  34. plasma level is associated with ischemic stroke subtypes PMID: 24048512
  35. Results suggest no association between R353Q polymorphism for factor VII and the presence or progression of coronary artery disease in the Iranian population. PMID: 24469878
  36. Identification of a homozygous mutation in exon 8 of coagulation FVII that is responsible for factor VII deficiency in a Chinese pedigree. PMID: 23672839
  37. Eight missense mutations were identified on the Factor 7 gene (p.Cys82Tyr, p.Cys322Ser, p.Leu357Phe, p.Thr410Ala, c-57C>T) PMID: 23731332
  38. Data indicate that nanobilayers containing phosphatidic acid (PA) bound substantially more of two proteins, factor VIIa and activated protein C, than did equivalent bilayers containing phosphatidylserine (PS). PMID: 23879866
  39. Data indicate that the interlaboratory precision was better for normal specimens than for factor VII (FVII) <20 U/dL with a mean coefficient of variation (CV) of 17.2% per specimen. PMID: 23590660
  40. Polymorphisms in the coagulation factor VII gene modulate the susceptibility to coronary artery disease in Tunisian Arabs. PMID: 22932775
  41. Rab GTPases regulate endothelial cell protein C receptor-mediated endocytosis and trafficking of factor VIIa. PMID: 23555015
  42. elevated FVII levels, and the -323P0/10 but not R353Q polymorphism, constitute risk factors for ACS. PMID: 23275237
  43. Data indicate that hfVII-LC and hIgG1-Fc can effectively inhibit tumor growth and metastases in SCID mice with tissue factor (TF) over-expressing colon cancer. PMID: 23494077
  44. Data suggest that plasma FVIIa-AT complex (coagulation factor VII-antithrombin III) is higher in portal vein thrombosis (PVT; without cirrhosis) than in healthy subjects; no difference in FVIIa-AT complex is observed in cirrhosis with/without PVT. PMID: 22958499
  45. Report comprehensive molecular analysis of FVII deficiency affected patients in North Tunisia. PMID: 22873696
  46. Prothromin genetic mutatation is one of the risk factor in the development of venous thromboembolism and myocardial infarction. PMID: 23382263
  47. glucose deprivation enhanced F7 expression in a mechanism reliant on prior ATF4 upregulation primarily due to increased transcription from the ATF4 gene. PMID: 22848420
  48. rs6046A allele in F7 associated with decreased blood pressure levels (PPMID: 22815813
  49. Intracellular depletion of GTP results in upregulation of coagulation factor VII. PMID: 23050902
  50. functional analysis of lethal factor VII deficiency due to novel mutations in the F7 promoter reveals disruption of HNF4 binding site PMID: 22628013
  51. Plasma coagulation factor VIIa - antithrombin complexes concentration had no predictive value for future cardiovascular disease in our study population. PMID: 21925715
  52. the F7 IVS6 1G>T mutation(c.681 1G>T; NM-019616.1), found in two homozygous FVII-deficientpatients with life-threatening bleeding symptoms, abrogates correct FVIImRNA processing but also activates an exonic cryptic 5'ss in cellularmodels. PMID: 22426302
  53. All probands have featured prolonged prothrombin time, with FVII activity ranging between 2.0% to 6.0%. PMID: 22875495
  54. Mutations in factor VII is associated with decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency. PMID: 22180436
  55. Letter: Endothelial cell protein C receptor does not appear to play a significant role in human factor VIIa clearance from plasma. PMID: 22372829
  56. FSAP activates single-chain urokinase-type plasminogen activator, but FVII appears remarkably resistant to activation. PMID: 22235940
  57. Human FVIIa binds efficiently to both murine and human EPCR. PMID: 22370814
  58. Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood. PMID: 22104068
  59. The FVII R353Q polymorphism is not associated with increased risk for cerebrovascular thrombosis occurring during the puerperal period in Indian women. PMID: 22136731
  60. Monoclonal antibodies allosterically augment the intrinsic activity of FVIIa through mechanisms distinct from that of TF. PMID: 22275370
  61. Epigenetic regulation through methylation of F7 promoter is associated with coronary artery disease by affecting plasma FVIIa concentrations in A1A1 genotypes. PMID: 22315437
  62. Preliminary findings revealed a possible contribution of the FVII -402GA polymorphism in the development of breast cancer. PMID: 20107938
  63. We here present the first characterization of a patient with severe FX deficiency due to the novel mutation c.162_165delAAGA and a co-existent large deletion involving both FVII and FX genes. PMID: 22126652
  64. Extrahepatic synthesis of FVII by colorectal cancer cells may promote tumor invasion and metastasis. PMID: 22166631
  65. rFVIIa-25C remained biochemically stable and aseptic during 24-hour continuous infusion in vitro at 19.3 degrees C to 20.7 degrees C, with no clinically significant changes in clot activity, solution constituents, or concentrations. PMID: 22088413
  66. The increase in FSAP is comparable in the seven OC-groups studied but is more significant in women carrying the 1601GG genotype than in women with the 1601GA genotype and results in increased activation of FVII PMID: 21737124
  67. Data suggest that antithrombin appears to play an active role in factor VIIa inhibition during cardiac surgery. PMID: 21569219
  68. Report pharmacokinetics, distribution, and excretion of 125I-labeled human plasma-derived-FVIIa and -FX with MC710 (FVIIa/FX mixture) in rats. PMID: 21621824
  69. Arg304Trp mutation in factor VII Padua (FVII Padua) showed discrepant activity levels that depend on the thromboplastin used in the assay system similar to the activity shown by the Arg304Gln mutation PMID: 21705315
  70. Prophylactic use of a recombinant activated factor VII in delivery haemorrhage by caesarean in a woman with major factor VII deficiency. PMID: 22123573
  71. The results made it possible to assume that the F7 and THBD genes play an important role in genetic predisposition to unfavorable outcomes in patients with a history of acute ischemic heart disease. PMID: 22232927
  72. The -60 T-->C mutation in the factor VII strongly diminishes functional interaction between the FVII promoter and transcription factor HNF4alpha contributing to severe factor VII deficiency in homozygous twins. PMID: 21760481
  73. Recombinant FVIIa modulates thrombin generation primarily by accelerating the process, without significantly affecting the total amount of generated thrombin. PMID: 21641634
  74. Data identified three new loci associated with FVII, of which APOA5 on chromosome 11q23 and HNF4A on chromosome 20q12-13 were replicated in a sample of 4289 participants from the Whitehall II study. PMID: 21676895
  75. the -323Ins10 polymorphism in factor VII gene is significantly associated with coronary heart disease (CHD) in both Asian and European populations, while R353Q polymorphism showed trend for association with CHD in Asians PMID: 21838885
  76. GlycoPEGylated rFVIIa (N7-GP) has a prolonged hemostatic effect in hemophilic mice compared with rFVIIa PMID: 21366858
  77. Arg 304 Gln mutation is equally or even more prevalent than the Ala 294 Val mutation in these FVII-deficient patients with thrombosis PMID: 21453389
  78. Study did not find a direct relationship between cardiovascular risk in patients with Heterozygous Familial Hypercholesterolemia, the R353Q polymorphism of factor VII and FVII Ag levels. PMID: 21477332
  79. Factor VII deficiency in Korea showed recurrent mutations in this population and suggested genotype-phenotype correlations. PMID: 21206266
  80. analysis of factor VIIa-catalyzed activation of factor VIII PMID: 20735721
  81. the F7 gene haplotype and genotype have effects on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men PMID: 20735728
  82. Polycations could present a new class of anticoagulants with such unique upstream downregulation of blood coagulation, selectively blocking tissue factor-dependent factor VII activation. PMID: 21184651
  83. Homozygous missense mutation of His348Gln was found in a pedigree of hereditary F VII deficiency. PMID: 21287501
  84. Plasma FVII levels are significantly elevated in women with pre-eclampsia. PMID: 21094984
  85. Colorectal cancer can ectopically synthesize coagulation factor VII. PMID: 19829668
  86. Data show that sleep deprivation significantly decreases the plasma activity levels of factor VII (FVII), which was even more pronounced at the liver mRNA level. PMID: 20418241
  87. heparanase is a potential modulator of blood hemostasis, and suggest a novel mechanism by which heparanase increases the generation of activated factor X in the presence of tissue factor and activated factor VII. PMID: 20634491
  88. analysis of worldwide distribution of the FVII Arg304Gln coagulation defect PMID: 20958793
  89. multiple logistic regression analysis revealed that two F7 polymorphisms, -670C and IVS7 seven or higher, are independent risk factors for ischemic stroke in young adult patients PMID: 20453637
  90. Factor VII (FVII) deficiency is the most frequent defect among the rare bleeding disorders. PMID: 21099211
  91. showed D allele of ACE to be associated with marginal risk of CHD, AA genotype of FACTOR VII R353Q and H6H7 and H7H7 genotypes of FACTOR VII VNTR showed protective effect for CHD. PMID: 20364300
  92. Results suggest that inhibition of FVIIa with small-molecule active-site inhibitors represents a promising antithrombotic approach. PMID: 20589312
  93. Data suggest that carbohydrate receptor(s) (e.g. the asialoglycoprotein receptor) play a role in hepatic asialo-rFVIIa and rFVIIa clearance. PMID: 20508904
  94. Review: Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. PMID: 20044773
  95. review of the interaction of recombinant factor VIIa with platelet glycoprotein Ib [review] PMID: 20153024
  96. factor VII and extravascular factor VIIa may have a role in hemophilic synovitis [review] PMID: 20227556
  97. review of Factor VIIa interaction with endothelial cells and endothelial cell protein C receptor [review] PMID: 20156643
  98. The F7 R353Q single nucleotide polymorphism appears to moderately influence plasma FVII coagulant activity and risk of coronary artery disease in Indians. PMID: 20086294
  99. No major associations between sleep and factor VII or fibrinogen were observed. PMID: 20651279
  100. Although heterozygous factor VII deficiency is generally recognized as clinically asymptomatic, this latent bleeding disorder can appear perioperatively or postoperatively in patients who undergo cardiopulmonary bypass procedures. PMID: 20197348

Show More

Hide All

Involvement in disease Factor VII deficiency (FA7D)
Subcellular Location Secreted
Protein Families Peptidase S1 family
Tissue Specificity Plasma.
Database Links

HGNC: 3544

OMIM: 227500

KEGG: hsa:2155

STRING: 9606.ENSP00000364731

UniGene: Hs.36989

Most popular with customers


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1